Swapnil Limkar

Indoco Remedies Ltd.

Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company's turnover is US$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. The Company's R&D team develops non-infringing processes for APIs, formulations and various dosage forms like Immediate Release Tablets, Capsules, Multi-Unit Pellet Systems (MUPS), PDDS, ER Tablets and nano suspensions, as well as a range of injectable solutions, suspensions and depot based long-acting injectables. Indoco has 8 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Stomatologicals, Gastro-Intestinal, Respiratory, Anti-Infectives, Vitamins/Minerals/Nutrients, Cold & Cough, Ophthalmics, Antifungal, Antidiabetic & Cardiovascular, Urology, and several others. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Cital UTI, Sensoform, Sensodent-KF, Cloben-G, Tuspel Plus, Dropizin, Tuspel LS, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Cal-Aid, Macuchek, Mofloren, Irivisc, PGVISC, Nepachek, Noxa, Subitral, Aloja, Glychek, etc. Indoco exports a variety of products to regulated and emerging markets, including the USA and EU. The Company has tie-ups with large generic companies and works in close coordination with its customers to leverage core competencies. Indoco's branded formulations are promoted and distributed across India and in Emerging Markets of South East Asia, Africa, Latin America and CIS. IAS division is USFDA approved and based at Navi Mumbai. It serves customers for their analytical research needs, utilizing state-of-utilizing state-of-the-art instruments and infrastructure.